William Whitford,
Strategic Solutions Leader,
GE Healthcare
Bill Whitford is Sr. Manager, Cell Culture, GE Healthcare in Logan, UT with over 20 years experience in biotechnology product and process development. He joined the company nine years ago as a team leader in R&D developing products supporting biomass expansion, protein expression and virus secretion in mammalian and invertebrate cell lines. Products he has commercialized include defined and animal product-free hybridoma media, fed-batch supplements, and aqueous lipid dispersions. An invited lecturer at international conferences, Bill has published over 250 articles, book chapters and patents in a number of fields in the bioproduction arena. He now enjoys such industry activities as serving on the editorial advisory board for BioProcess International.
Continuous Bio-manufacturing of Extracellular Vesicle Reference Materials
Friday, 6 October 2017 at 12:00
Add to Calendar ▼2017-10-06 12:00:002017-10-06 13:00:00Europe/LondonContinuous Bio-manufacturing of Extracellular Vesicle Reference MaterialsLiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Interest in microvesicles, exosomes and oncosomes is growing. Applications include 1) vectors of research or therapeutic cargo, 2) agents of intercellular communication from stems cells to terminally differentiated tissue to the entire microbiome and 3) support of clinical diagnostics. There are ongoing efforts to standardize clinically applied vesicle assays and therapeutic cargo vehicles. Reference materials, controls, and performance standards need to be defined for quality assurance in such applications. Certified reference materials (such as from the NIST or ATCC) and secondary materials may need to be generated for CLEA regulated diagnostic or therapeutic activities. Sponsors often have their choice of cell platforms, production formats and culture modes for vesicle product and process development. However, commercial success can be dependent upon the discovery of scalable technologies that can produce very large amounts of sufficiently pure vesicles in a robust, compliant and cost-effective manner in a cGMP environment. In biopharmaceuticals, continuous biomanufacturing promises heightened process flexibility and a reduction in product microheterogeneity; construction costs and schedule extent; utilities requirement; manufacturing suite area and classification. The value of single-use implemented continuous biomanufacturing with chemically defined animal product-free materials will be reviewed.
Add to Calendar ▼2017-10-05 00:00:002017-10-06 00:00:00Europe/LondonLiquid Biopsies and Minimally-Invasive Diagnostics 2017Liquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
Add to Calendar ▼2017-10-06 12:00:002017-10-06 13:00:00Europe/LondonContinuous Bio-manufacturing of Extracellular Vesicle Reference MaterialsLiquid Biopsies and Minimally-Invasive Diagnostics 2017 in Coronado Island, CaliforniaCoronado Island, CaliforniaSELECTBIOenquiries@selectbiosciences.com
_150x75.jpg)
.gif){kind=logo}